



CERTIFICATE OF COMPLETION

THE UNIVERSITY OF WASHINGTON AND THE NATIONAL HIV CURRICULUM CERTIFY THAT

Katherin Marleny Castaneda Garcia, BS

HAS COMPLETED THE FOLLOWING LESSONS IN THE

CO-OCCURRING CONDITIONS 3RD EDITION MODULE

Latent Tuberculosis Infection, and Opportunistic Infections: Prevention

A handwritten signature in black ink that reads "David Spach, MD".

David H. Spach, MD
Editor-in-Chief, National HIV Curriculum
Professor of Medicine, University of Washington

This certificate shows the progress of **Katherin Marleny Castaneda Garcia, BS**, a Biological Chemistry, identified by **katherinc.qb@gmail.com** as of June 14, 2026, 10:52 pm. You may validate this certificate or obtain a digital copy by visiting <https://www.hiv.uw.edu/certificate/co-occurring-conditions/katherinc.qb@gmail.com/3>

The following Lessons were completed along with their quizzes with a quiz score of 80% or higher:

Lessons	Learning Objectives
<p>Latent Tuberculosis Infection</p> <p>Completed February 4, 2024</p>	<ul style="list-style-type: none"> • Discuss the epidemiology of tuberculosis and HIV coinfection in the United States • State the rationale for screening for latent TB in people with HIV • Describe and compare recommended screening tests for latent TB in people with HIV • List recommended options for the treatment of latent TB in people with HIV • Summarize common drug interactions between medications used to treat latent TB and common antiretroviral medications
<p>Opportunistic Infections: Prevention</p> <p>Completed February 20, 2024</p>	<ul style="list-style-type: none"> • Discuss recommendations for initiating primary prevention of opportunistic infections in people with HIV • Summarize recommendations for initiating secondary prophylaxis of opportunistic infections in people with HIV • State criteria for discontinuing primary prevention of opportunistic infections in people with HIV • List criteria for discontinuing secondary prophylaxis of opportunistic infections in people with HIV • Recognize potential adverse effects and contraindications for medications used for prevention of opportunistic infections